Compass Pathways (NASDAQ:CMPS) Shares Gap Up – What’s Next?

Posted by Brenda Bartman on Jul 16th, 2026

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS – Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $13.31, but opened at $14.50. Compass Pathways shares last traded at $13.08, with a volume of 2,592,055 shares changing hands.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. B. Riley Financial assumed coverage on Compass Pathways in a research report on Friday, April 24th. They set a “buy” rating and a $17.00 price objective on the stock. Compass Point set a $25.00 price target on Compass Pathways in a research report on Tuesday, July 7th. Wolfe Research reiterated an “outperform” rating on shares of Compass Pathways in a research note on Tuesday, July 7th. Maxim Group boosted their price objective on Compass Pathways from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Finally, UBS Group set a $18.00 target price on shares of Compass Pathways in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $24.15.

Get Our Latest Stock Report on Compass Pathways

Compass Pathways Stock Performance

The company has a quick ratio of 3.32, a current ratio of 3.32 and a debt-to-equity ratio of 0.15. The firm has a 50-day simple moving average of $12.24 and a 200 day simple moving average of $8.77. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -4.19 and a beta of 2.47.

Compass Pathways (NASDAQ:CMPS – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. On average, sell-side analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Compass Pathways

A number of institutional investors have recently modified their holdings of CMPS. Corient Private Wealth LLC lifted its stake in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock valued at $265,000 after purchasing an additional 1,200 shares during the period. EverSource Wealth Advisors LLC grew its position in Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares during the period. Conservest Capital Advisors Inc. increased its holdings in Compass Pathways by 24.6% in the fourth quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after buying an additional 5,000 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Compass Pathways during the 4th quarter valued at approximately $38,000. Finally, Raymond James Financial Inc. boosted its stake in shares of Compass Pathways by 82.7% during the 3rd quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock worth $79,000 after acquiring an additional 6,228 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Pathways

(Get Free Report)

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.